Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795659 · ClinicalTrials.gov registry record · Phase 1
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT06795659 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 4 participants.
The verdict
NCT06795659, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD) to enhance treatment benefits. Ketamine nasal spray is a drug approved by the U.S. Food \& Drug Administration (FDA) for treatment resistant depression. Combined with PE, intranasal ketamine may help to augment PE and further reduce participants' PTSD symptoms.
Interventions
- BEHAVIORAL Massed Prolonged Exposure (PE)
- DRUG Esketamine (Intranasal Spray)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2026-01-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06795659
The ClinicalTrials.gov registry entry for NCT06795659 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Massed Prolonged Exposure (PE) is the first listed.
NCT06795659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06795659 about?
NCT06795659 is a clinical study titled "Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)". This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatm...
What is the current status of trial NCT06795659?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2025-06-09. Estimated completion is 2026-01-16.
What interventions are being tested in trial NCT06795659?
The interventions under investigation include: Massed Prolonged Exposure (PE) (BEHAVIORAL), Esketamine (Intranasal Spray) (DRUG).
Who is sponsoring clinical trial NCT06795659?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.